Surface Oncology, Inc. (NASDAQ:SURF – Get Rating) CEO Robert W. Ross sold 10,594 shares of the company’s stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $1.72, for a total value of $18,221.68. Following the completion of the sale, the chief executive officer now owns 99,906 shares in the company, valued at $171,838.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Surface Oncology Price Performance
Surface Oncology stock traded down $0.02 on Friday, reaching $1.78. The company’s stock had a trading volume of 857,629 shares, compared to its average volume of 717,498. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.42 and a current ratio of 9.42. The company has a market cap of $97.21 million, a price-to-earnings ratio of -1.38 and a beta of 1.60. The business’s fifty day moving average price is $1.80 and its 200 day moving average price is $2.48. Surface Oncology, Inc. has a twelve month low of $1.37 and a twelve month high of $8.38.
Surface Oncology (NASDAQ:SURF – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.61. Surface Oncology had a negative return on equity of 47.56% and a negative net margin of 182.63%. The company had revenue of $30.00 million for the quarter. Equities analysts expect that Surface Oncology, Inc. will post -1.19 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Surface Oncology
Wall Street Analysts Forecast Growth
Separately, Jonestrading reiterated a “buy” rating and issued a $12.00 price target on shares of Surface Oncology in a research report on Sunday, June 5th.
About Surface Oncology
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8.
- Get a free copy of the StockNews.com research report on Surface Oncology (SURF)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.